NASDAQ:BBLG - Nasdaq - US0980705018 - Common Stock - Currency: USD
NASDAQ:BBLG (4/23/2025, 1:15:14 PM)
0.7158
+0.01 (+1.52%)
The current stock price of BBLG is 0.7158 USD. In the past month the price decreased by -17.05%. In the past year, price decreased by -53.91%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.4 | 311.43B | ||
AMGN | AMGEN INC | 14.05 | 149.73B | ||
GILD | GILEAD SCIENCES INC | 22.94 | 131.86B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1700.55 | 126.78B | ||
REGN | REGENERON PHARMACEUTICALS | 12.95 | 64.59B | ||
ARGX | ARGENX SE - ADR | 322.59 | 36.64B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.51B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.80B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.01B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 22.86B | ||
NTRA | NATERA INC | N/A | 20.44B | ||
BIIB | BIOGEN INC | 7.18 | 17.31B |
Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
BONE BIOLOGICS CORP
2 Burlington Woods Dr Ste 100
Burlington MASSACHUSETTS US
Employees: 2
Company Website: https://www.bonebiologics.com/
Investor Relations: http://www.bonebiologics.com/investor-relations/
Phone: 17815524452
The current stock price of BBLG is 0.7158 USD. The price increased by 1.52% in the last trading session.
The exchange symbol of BONE BIOLOGICS CORP is BBLG and it is listed on the Nasdaq exchange.
BBLG stock is listed on the Nasdaq exchange.
7 analysts have analysed BBLG and the average price target is 16.83 USD. This implies a price increase of 2251.22% is expected in the next year compared to the current price of 0.7158. Check the BONE BIOLOGICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BONE BIOLOGICS CORP (BBLG) has a market capitalization of 2.34M USD. This makes BBLG a Nano Cap stock.
BONE BIOLOGICS CORP (BBLG) currently has 2 employees.
BONE BIOLOGICS CORP (BBLG) has a support level at 0.7 and a resistance level at 0.74. Check the full technical report for a detailed analysis of BBLG support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BBLG does not pay a dividend.
BONE BIOLOGICS CORP (BBLG) will report earnings on 2025-05-12, after the market close.
BONE BIOLOGICS CORP (BBLG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.96).
The outstanding short interest for BONE BIOLOGICS CORP (BBLG) is 6.04% of its float. Check the ownership tab for more information on the BBLG short interest.
ChartMill assigns a fundamental rating of 2 / 10 to BBLG. No worries on liquidiy or solvency for BBLG as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months BBLG reported a non-GAAP Earnings per Share(EPS) of -4.96. The EPS increased by 92.52% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -189.7% | ||
ROE | -210.26% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to BBLG. The Buy consensus is the average rating of analysts ratings from 7 analysts.